

Gilead Sciences Bosnia & Herzegovina EFPIA Report 2022  
(in accordance with Article 20 (3) of the UIPL Code)

Date of Publication: 30/06/2023

	Full Name  (Ar. 19.1.)	HCPs: City of Principal Practice HCOs: City Where Registered  (Ar. 20.6)	Country of Principal Practice  (Ar. 20.6. in conjunction to Ar. 21.)	Principal Practice Address  (Ar. 20.6.)	Unique Country Identifier (optional)  (Ar. 20.6.)	Donations to HCOs  (Ar. 21.1.A.(i))	Contribution to Costs of Events (Ar. 21.1.A.(ii)   21.1.B(i))			Fee for Service and Consultancy (Ar. 21.1.A.(iii)   21.1.B(ii))		TOTAL OPTIONAL	
							Sponsorship agreements with HCOs/third parties appointed by HCOs to manage an event	Registration Fees	Travel and Accommodation	Fees	Related expenses agreed in the fee for service or consultancy contract, including travel & accommodation relevant to the contract		
HCPs	INDIVIDUAL NAMED DISCLOSURE - one line per HCP (i.e. all transfers of value during a year for an individual HCP will be summed up; itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)												
	OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons												
	Aggregate amount attributable to Transfers of Value to such Recipients – Ar. 21.2.						N/A	N/A	16,372.11 KM	30,665.10 KM	20,533.06 KM	1,625.21 KM	69,195.48 KM
	Number of Recipients in aggregate disclosure – Ar. 21.2.						N/A	N/A	21	22	16	3	32
% of the number of Recipients included in the aggregate disclosure in the total number of Recipients – Ar. 21.2.						N/A	N/A	100%	100%	100%	100%	100%	
HCOs	INDIVIDUAL NAMED DISCLOSURE - one line per HCO (i.e. all transfers of value during a year for an individual HCO will be summed up; itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)												
	OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons												
	Aggregate amount attributable to Transfers of Value to such Recipients – Ar. 21.2.												
	Number of Recipients in aggregate disclosure – Ar. 21.2.												
% of the number of Recipients included in the aggregate disclosure in the total number of Recipients – Ar. 21.2.													
R&D	AGGREGATE DISCLOSURE												
	Transfer of Values for Research and Development as defined in Article 21.2.2.											69,195.48 KM	